Home > Julie Graff, ESMO 2019 – KEYNOTE-641 study in prostate cancer
Prostate Cancer

Julie Graff, ESMO 2019 – KEYNOTE-641 study in prostate cancer

Published Online: October 8th 2019

We met with Julie Graff (Knight Cancer Institute) at ESMO 2019 to discuss unmet needs in the treatment of metastatic castration-resistant prostate cancer and KEYNOTE-641 (NCT03834493), a phase III study of pembrolizumab plus enzalutamide in this patient population.

Questions
1.     What are the current unmet needs in the treatment of metastatic castration-resistant prostate cancer (mCRPC) with androgen receptor inhibitors? (0:05)
2.     Could you tell us a little about the aims and design of the KEYNOTE-641 study? (0:50)
3.     What are the eligibility criteria for this study? (1:23)
4.     How can we overcome the challenge of identifying biomarkers predictive of response to pembrolizumab? (1:55)
5.     What other combined therapeutic approaches involving androgen receptor inhibitors are being investigated in the treatment of mCRPC? (2:51)

Filmed at the European Society for Medical Oncology (ESMO) Congress 2019, Barcelona, Spain.

Speaker disclosure: Julie Graff has received travel expenses from Sanofi.

touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.

Share this Video
Related Videos In Prostate Cancer
Prostate Cancer
Axel Merseburger: International Men’s Day and EU Prostate Cancer Day and the Importance of Raising Awareness of Men’s Health and Well-being

Prof Axel S Merseburger (University of Lübeck, Lübeck, Germany), gives his thoughts on the importance of International Men’s Day and EU Prostate Cancer Day in raising awareness of men’s health and well-being. Question International Men’s Day and EU Prostate Cancer Day are both held in November. What is the importance of raising awareness of male […]

Prostate Cancer
Axel S Merseburger, ESMO 2021: Highlights and Key Data in Advanced Prostate Cancer

touchONCOLOGY joins our Editor-in-Chief Prof Axel S Merseburger (University of Lübeck, Lübeck, Germany), to discuss the key data presented at the ESMO Congress 2021 in the field of advanced prostate cancer and the significant impact these advances have on clinical practice. Questions 1. What were the hottest topics and exciting new research from the ESMO […]

Prostate Cancer
Neeraj Agarwal, ESMO 2021: Results of Expanded Cohort 6 of the COSMIC-021 Study

touchONCOLOGY joins Professor Neeraj Agarwal (Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA) at ESMO 2021 to discuss the much-anticipated results of the COSMIC-021 study of cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer. Questions 1. What is the rationale for the combined use of cabozantinib and atezolizumab […]

Trending In Prostate Cancer:

Axel Merseburger: International Men’s Day and EU Prostate Cancer Day and the Importance of Raising Awareness of Men’s Health and Well-being
Prostate Cancer
    • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72